Myleran (Busulfan)

Busulfan, the active ingredient in Myleran, is an alkylating agent presented as an oral formulation for oral use. It is employed in the treatment of chronic myelogenous leukemia and serves as a conditioning component in bone marrow transplantation protocols.

GNH USA supplies Myleran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across multiple markets.

Busulfan, an alkylating agent, is used in hematologic malignancies and as part of conditioning regimens for stem cell transplantation.

- Chronic myelogenous leukemia: reduces leukemic cell proliferation and contributes to disease remission. - Bone marrow transplantation (conditioning regimen): eradicates residual host marrow cells to enable successful engraftment of donor stem cells. - Acute myeloid leukemia (pre‑transplant preparation): provides cytoreduction before allogeneic transplantation in selected protocols. - Myelodysplastic syndromes (intensive therapy): used in combination regimens to achieve disease control prior to transplant. - Chronic myeloproliferative disorders (as part of combination therapy): helps control disease burden before definitive treatment.

Busulfan may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, may require antiemetic therapy. - Mucositis: inflammation of the oral mucosa causing discomfort. - Alopecia: temporary hair loss during treatment. - Fever: low‑grade pyrexia without infection.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue, may be irreversible. - Hepatic veno‑occlusive disease: obstruction of hepatic venules leading to liver dysfunction. - Seizures: central nervous system events, especially at high plasma concentrations. - Severe bone marrow suppression: profound neutropenia, anemia, and thrombocytopenia increasing infection and bleeding risk. - Secondary malignancies: rare development of new cancers after prolonged exposure.

When using Busulfan, careful monitoring and specific precautions are recommended to minimize toxicity. - Dose adjustment: required in patients with hepatic impairment or reduced glutathione S‑transferase activity. - Monitor blood counts: perform regular CBCs to detect myelosuppression early. - Avoid in pulmonary disease: increased risk of fibrosis warrants caution in pre‑existing lung conditions. - Contraception: both male and female patients should use effective contraception during treatment and for a defined period after. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Busulfan can interact with several medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid): - Azathioprine: additive myelosuppression may lead to severe bone marrow failure. - Cyclophosphamide: combined alkylating effect raises risk of organ toxicity. - Chloramphenicol: inhibits hepatic metabolism, increasing busulfan plasma levels.

Moderate Interactions (Monitor Closely): - Phenytoin: enzyme induction may lower busulfan concentrations, reducing effectiveness. - Itraconazole: strong CYP3A4 inhibition can raise busulfan exposure, requiring dose adjustment. - Acetaminophen: high doses may compete for conjugation pathways, affecting clearance.